Skip to content

Internet Explorer is no longer supported by this website.

For optimal browsing we recommend using Chrome, Firefox or Safari.
Heart icon (animated) heart icon (static)
Our Businesses
Explore more Johnson & Johnson sites:
Switzerland
Page logo

Janssen and Johnson & Johnson to Present Latest Phase 3 Results for Canagliflozin in the Treatment of Patients with Type 2 Diabetes
Janssen and Johnson & Johnson to Present Latest Phase 3 Results for Canagliflozin in the Treatment of Patients with Type 2 Diabetes

New Brunswick, NJ (September 26, 2012) – Janssen Research & Development, LLC and Johnson & Johnson will provide a pre-recorded webcast for investors and other interested parties on Tuesday, October 2, at approximately 12:00 p.m., Eastern Time, to coincide with the 48th European Association for the Study of Diabetes (EASD) Annual Meeting in Berlin, Germany.

First results from the ongoing phase 3 CANVAS trial evaluating canagliflozin in patients with type 2 diabetes at elevated risk for cardiovascular disease will be shown at EASD.  Additionally, data from DIA3010, which evaluated canagliflozin as add-on therapy in patients aged 55 to 80, on antihyperglycemic therapy without adequate glycemic control, will be presented.

A pre-recorded webcast with Kirk Ways, M.D., Ph.D, Vice President and compound development team leader for canagliflozin from Janssen Research & Development, will provide an update on the CANVAS sub-study and DIA3010 results.

The webcast/podcast can be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com and clicking on “Webcasts/Presentations.”

###

Press Contacts:
Al Wasilewski
(732) 524-1130

Bill Price
(732) 524-6623

Investor Contacts:
Stan Panasewicz
(732) 524-2524

Louise Mehrotra
(732) 524-6491

Back to top
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue